ePRO: A Maturing and Widely-Preferred Market
Industry Standard Research
The adoption of technologies is generally increasing throughout clinical trials. It took the industry some time to fully adopt and integrate EDC as the de facto standard for data collection but that has happened. ISR's data show EDC is now the data collection method of choice for the vast majority of clinical trials. We're also witnessing the maturation of other technologies in clinical trials such as online dashboards that aggregate clinical trial metrics and report on study progress; we see clinical sites relying more heavily on their electronic medical records for feasibility and patient recruitment; and we find clinical investigators and study coordinators prefer electronic patient reported outcomes (ePRO) over paper PRO.
The stage is set for further proliferation of not only ePRO, but a much broader set of eClinical service offerings and value propositions. Service providers, technology developers, and CROs need to know where their products stand and sponsors should be aware of how their partners are viewed by one of the most important cogs in the clinical development wheel: the investigative sites.
—Industry Standard Research, www.ISRreports.com/.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
